

Mental Health Medication Advisory Committee Meeting
Meeting Minutes, Open Session
May 14, 2019 2:00pm – 4:30 p.m.

<p>MHMAC Open Session DXC Technology Capital Room 6511 Forbes Ave. Topeka, KS 6619</p>	<p>Committee Members Present: DeAnn Jenkins, MD (Chair) Vishal Adma, MD Taylor Porter, MD Charles Millhuff DO</p> <p>Committee Members Absent: Nicole Ellermeier, PharmD Bradley Grinage, MD Karen Moeller, PharmD</p> <p>KDHE/Contractor Staff Present: Annette Grant, RPh, Victor Nguyen, PharmD Margaret O'Donnell, Transcriptionist</p> <p>MCO Representatives Present: Jeanne M. Cavanaugh, PharmD – UnitedHealthcare Angie Zhou, PharmD – Sunflower Health Plan Alan Carter, PharmD – Aetna Better Health of Kansas</p> <p>DXC/HID Staff Present: Kathy Kaesewurm, RN, BSN</p>	<p>Representatives: Ellen Spivey, Chris Fose, Tim Meier, Jacqueline Dyke, KDHE; Sallie Page- Goertz, KU; Chris Beal, Rick Kegler, Otsuka; Dawn Lease, J&J; Erin Hohman, Janssen; Kristin Farmer, KDADS; Brandon Kennedy, CMH; Jason Duhon, Navigant</p> <p>*Illegible names on sign-in sheet were not included.</p>
--	---	--

	DISCUSSION	
I. Call to Order A. Introduction B. Announcements	Call to Order: Dr. Jenkins called the meeting to order at 2:10 p.m. Announcements: *Standard parking lot notice	
II. Old Business A. Review and approval of February 12, 2019 Meeting Minutes	Committee Discussion: First page under Committee Members Present should have Dr. Jenkins listed as absent. The minutes will be amended to show this correction.	Decision and/or Action: Dr. Adma moved to approve the minutes as amended. Dr. Porter seconded the motion. The minutes were approved as amended.
III. New Business A. Prior Authorization Criteria 1. Antidepressant Medications – Safe Use for All Ages	Background: Ms. Grant proposed adding (Esketamine) Spravato™ to the PA criteria, as a separate section and criteria. Clinical Public Comment: Erin Hohman and Dawn Lease with Johnson & Johnson spoke on behalf of Spravato™.	

<p>III. New Business A. Prior Authorization Criteria 1. Antidepressant Medications – Safe Use for All Ages (Continued)</p>	<p>Committee Discussion: The Committee agreed to replace the word “adequate” dose with “therapeutic” dose in sub-bullet two. An MCO requested clarification on what is an adequate duration and requested to add “in the current episode” in parentheses after “inadequate response”. There was discussion that six weeks represents an adequate duration, therefore, the second sub-bullet was changed to “Inadequate response (in the current episode) to at least 2 different antidepressants despite therapeutic dose and 6 weeks duration of each medication.” The Committee agreed to change 4th bullet to “Patient must be screened for active/risk for substance use disorder.” The Committee agreed to add bullet “Prescriber has addressed the appropriateness of psychotherapy with the patient.” An amendment to the renewal criteria was also made by removing “significantly improved score on a validated rating scale, ability to return to work, etc.” to “patient is in remission or partial remission.”</p>	<p>Decision and/or Action: Dr. Porter moved to approve the criteria as amended. Holly Cobb, APRN, seconded the motion. The motion was approved, as amended.</p>
<p>III. New Business A. Prior Authorization Criteria 2. Multiple Concurrent Mental Health Medication PA – For All Ages</p>	<p>Background: Due to claims review and provider concerns, there is a need to have prior authorization to address multiple concurrent mental health medication use.</p> <p>Committee Discussion: A committee member requested data on the number of patients taking five or more mental health drugs, which the State presented data from calendar year 2017. General discussion was had, and it was agreed that it would be helpful for the committee to have data on the number of mental health medications per patient broken down by those on four, five, and six drugs per age base, to know how many PAs are coming in, the number of unique prescribers, etc. The Committee agreed to remove the 2nd bullet under Criteria for Multiple Concurrent Mental Health Medications.</p>	<p>Decision and/or Action: Dr. Porter moved to table the agenda item until more data is available. Dr. Adma seconded the motion. The motion to table the agenda item carried unanimously.</p>

<p>III. New Business</p> <p>B. Management of Medications Not Addressed in Their Associated Class PA</p>	<p>Background:</p> <p>There are areas of clinical concern which will be monitored via non-prior authorization methods. A summary of any passed items addressed, but then determined to not include in a PA, was given by the state.</p> <ol style="list-style-type: none"> 1. Trazadone & Mirtazapine – Not included in the Antidepressant - Safe Use for All Ages PA due to being commonly used as a sleep aid. 2. Patients ≥65 yrs. old, not in an LTC facility, who have dementia, without a proper diagnosis. 3. Multiple Mood Stabilizers used concurrently. 4. Concurrent use of an opioid and a benzodiazepine. 5. Concurrent use of an opioid and an antipsychotic. <p>The items listed above will be managed by one or more of the following methods: Retro-Drug Utilization Review, soft edits at the Point of Sale, provider education, and/or peer-to-peer review.</p> <p>Committee Discussion:</p> <p>There was general discussion concerning data presented by Ms. Grant. The Committee discussed the educational benefits it hopes to give to providers by managing these medications in this fashion.</p>	<p>Decision and/or Action:</p> <p>No decisions needed. Presentation only.</p>
<p>IV. Open Public Comment</p>	<p>Clinical Public Comment:</p> <p>None.</p>	
<p>V. Adjourn</p>	<p>Dr. Porter moved to adjourn.</p> <p>Dr. Adma seconded the motion.</p> <p>Dr. Jenkins adjourned the meeting at 4:10 p.m.</p>	

The next MHMAC meeting is scheduled for August 13, 2019.